ArticleParkinson's disease2021
Characterizing Advanced Parkinson's Disease: Romanian Subanalysis from the OBSERVE-PD Study.
Article in Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Next-generation pharmacological strategies for Parkinson's disease: a systematic literature review of symptom management and disease modification.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Long-Term Clinical Efficacy, Safety, and Polypharmacy Simplification of Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: An 18-Month Longitudinal Study.Journal of clinical medicine · 2026Article
- Clinical Outcomes and Predictors of Response to Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: A Retrospective Cohort Study over a 4-Year Period.Pharmaceutics · 2026Article
- Alignment of 5-2-1 criteria with Neurologists' clinical judgment in identifying Advanced Parkinson's Disease in Morocco: A cross-sectional inter-rater agreement study.BMC neurology · 2026Article
- Long-Term Effectiveness and Safety of LCIG in Romania. 3-year Results from a Prospective, Observational Study (DUOGLOBE).Neuropsychiatric disease and treatment · 2026Article
- Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study.Movement disorders clinical practice · 2026Observational
- Target-Controlled Sedation with Propofol Infusion for PEG-J Placement in Advanced Parkinson's Disease: A Prospective Observational Study on Safety and Feasibility.Life (Basel, Switzerland) · 2025Article
- Drug utilization study of antiparkinsonian medication in Romania during 25 years.Frontiers in pharmacology · 2025Article
- Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience.Pharmaceutics · 2024Article
- Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson's disease patients.Scientific reports · 2024Article
- Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Imaging Criteria for the Diagnosis of Progressive Supranuclear Palsy: Supportive or Mandatory?Diagnostics (Basel, Switzerland) · 2023Article
- Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease.Neuropsychiatric disease and treatment · 2023Review
- Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.Acta neurologica Scandinavica · 2022Observational
- Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Observations and Dilemmas after 10 Years of Real-Life Experience.Pharmaceutics · 2022Article
- Advanced Parkinson's Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis.Brain sciences · 2021Article
- Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson's Disease.Brain sciences · 2021Article
- Advanced Parkinson's disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study.Neurodegenerative disease managementArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OBSERVE-PD was a cross-sectional, multicountry, observational study conducted in 128 Movement Disorders Centers (MDCs) in 18 countries. Overall, the study enrolled 2615 patients. The aim was to determine the proportion of patients with advanced Parkinson's disease (APD) versus non-APD from MDCs and to uncover the clinical burden of APD, as well as a correlation between overall assessment of APD and several indicators of APD. The advanced stage of the disease and severity were assessed by investigators using their clinical judgement. Data were collected during a single visit between February 2015 and January 2016. Agreement on physician judgement of APD diagnosis and fulfillment of at least one previously established APD indicator was calculated. Motor and nonmotor symptoms (NMSs), activities of daily living, treatment complications, quality of life (QoL), conventional treatments, and device-aided therapy (DAT) eligibility were assessed. Here, country-specific results of 161 Romanian patients with PD are presented. In total, 59.0% of patients were diagnosed with APD and 78.8% met at least one APD indicator. There was only moderate agreement between clinical judgement of APD and overall fulfillment of APD indicators. All scores related to motor symptoms, NMSs, and treatment complications, as well as to QoL, showed a higher disease burden for patients with APD versus non-APD. Physicians considered 73.7% of patients with APD eligible for DAT. The majority of patients eligible for DAT (54.3%) did not receive such treatment. Our results highlight the importance of earlier recognition of APD, by combining clinical judgement with more standardized clinical tools, such as generally recognized APD criteria. However, timely diagnosis of APD alone is not enough to improve patient outcomes. Other critical factors include patient acceptance and access to appropriate treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.